Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Phone415-910-5717
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable
Cortexyme (NASDAQ:CRTX) Frequently Asked Questions
What is Cortexyme's stock symbol?
Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."
How were Cortexyme's earnings last quarter?
Cortexyme, Inc. (NASDAQ:CRTX) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.00. View Cortexyme's Earnings History.
When is Cortexyme's next earnings date?
What price target have analysts set for CRTX?
3 Wall Street analysts have issued 12-month price targets for Cortexyme's shares. Their forecasts range from $14.00 to $53.00. On average, they anticipate Cortexyme's share price to reach $34.25 in the next twelve months. This suggests that the stock has a possible downside of 43.0%. View Analyst Price Targets for Cortexyme.
What is the consensus analysts' recommendation for Cortexyme?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cortexyme.
Has Cortexyme been receiving favorable news coverage?
News stories about CRTX stock have been trending very negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cortexyme earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Cortexyme.
Are investors shorting Cortexyme?
Cortexyme saw a drop in short interest in January. As of January 31st, there was short interest totalling 1,410,000 shares, a drop of 9.0% from the January 15th total of 1,550,000 shares. Based on an average trading volume of 180,500 shares, the short-interest ratio is presently 7.8 days. Currently, 15.6% of the company's shares are short sold. View Cortexyme's Current Options Chain.
Who are some of Cortexyme's key competitors?
What other stocks do shareholders of Cortexyme own?
Who are Cortexyme's key executives?
Cortexyme's management team includes the folowing people:
- Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
- Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
- Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
- Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
- Dr. Michael J. Detke, Chief Medical Officer (Age 52)
When did Cortexyme IPO?
(CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who are Cortexyme's major shareholders?
Cortexyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Capital International Investors (3.57%), Capital World Investors (2.13%), State Street Corp (0.66%), Geode Capital Management LLC (0.40%), Marshall Wace North America L.P. (0.39%) and Charles Schwab Investment Management Inc. (0.16%). Company insiders that own Cortexyme stock include Epiq Capital Group, Llc and Pfizer Inc. View Institutional Ownership Trends for Cortexyme.
Which major investors are selling Cortexyme stock?
Which major investors are buying Cortexyme stock?
CRTX stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, State Street Corp, Marshall Wace North America L.P., Capital International Investors, Geode Capital Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc. and Rhumbline Advisers. Company insiders that have bought Cortexyme stock in the last two years include Epiq Capital Group, Llc and Pfizer Inc. View Insider Buying and Selling for Cortexyme.
How do I buy shares of Cortexyme?
Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cortexyme's stock price today?
One share of CRTX stock can currently be purchased for approximately $60.08.
How big of a company is Cortexyme?
What is Cortexyme's official website?
How can I contact Cortexyme?
Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]
MarketBeat Community Rating for Cortexyme (NASDAQ CRTX)
MarketBeat's community ratings are surveys of what our community members think about Cortexyme and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
